New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

Core Insights - Resmed announced a landmark meta-analysis published in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea (OSA) [1][3]. Group 1: Study Findings - The meta-analysis included data from over 1 million OSA patients across 30 studies, providing the strongest evidence to date that CPAP therapy alleviates OSA symptoms and prolongs life [3][4]. - CPAP therapy users have a 37% lower risk of dying from any cause and a 55% lower risk of dying from cardiovascular disease compared to those who do not use CPAP [6]. - There is a dose-response relationship indicating that more consistent CPAP use correlates with greater survival benefits for OSA patients [6]. Group 2: Health Implications - OSA affects over one billion people globally, with over 80% of cases undiagnosed and untreated, leading to serious health conditions such as hypertension, diabetes, and cardiovascular disease [2][3]. - The study emphasizes that untreated OSA is a major modifiable risk factor for all-cause and cardiovascular-related death, highlighting the importance of consistent CPAP use [2][4]. Group 3: Expert Commentary - Experts in sleep and respiratory medicine assert that CPAP therapy is a life-saving intervention for OSA patients, supporting heart health and extending life [4]. - The findings serve as a wake-up call, indicating that every additional hour of CPAP treatment improves survival chances for OSA patients [4].